Intarcia Therapeutics just released the latest data from its phase 3 FREEDOM-1 trial of ITCA-650, a small implanted device to treat type 2 diabetes. The tiny device is implanted under the skin for three or six months and continuously releases exenatide (a GLP-1 agonist) through a small mini-pump.